GLUE
Monte Rosa Therapeutics, Inc.
Latest close $16.08 as of Aug 4, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 3 parsed filing(s)| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates CIK0000080255 | Jun 30, 2026 observed Jul 8, 2026 filed · 8d Schedule 13G amendment | Reported accumulation | 8.9M +4.2M | 12.00% 0.00 pts | $24.20 | $24.06 | $16.08 |
| T. Rowe Price Associates CIK0000080255 | Sep 30, 2025 observed Nov 14, 2025 filed · 45d Schedule 13G amendment | Earliest Schedule 13G amendment found | 4.6M | 12.00% | $16.08 | ||
| BlackRock Legacy CIK0001364742 | Dec 31, 2023 observed Feb 14, 2024 filed · 45d Schedule 13G amendment | Earliest Schedule 13G amendment found | 2.4M | 4.70% | $4.76 | $16.08 |